◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › T › TWST

Twist Bioscience Corp (TWST) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DIAGNOSTICS & RESEARCH · DATA UPDATED 2026-08-13

Twist Bioscience Corp (TWST) operates in the DIAGNOSTICS & RESEARCH industry and is headquartered in South San Francisco, United States with about 979 employees. Its market capitalization is roughly $11 billion. In the fiscal year ended 2025-09-30, TWST reported $377M in revenue and ($78M) in net income.

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products.

Interactive charts & full statements → Open the TWST valuation workbench →

TWST Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Total Revenue	$432M	$377M	$313M	$245M	$204M	$132M	$90M	$54M	$25M	$11M	$2M
Gross Profit	$224M	$191M	$133M	$90M	$84M	$52M	$29M	$7M	($7M)	($13M)	($7M)
Gross Margin %	52.0%	50.7%	42.6%	36.6%	41.4%	39.1%	31.9%	12.8%	-26.6%	-123.1%	-315.2%
Operating Income (EBIT)	($138M)	($136M)	($221M)	($217M)	($249M)	($153M)	($140M)	($109M)	($71M)	($58M)	($44M)
Operating Margin %	-31.9%	-36.2%	-70.6%	-88.6%	-122.3%	-115.4%	-155.5%	-200.2%	-277.5%	-543.2%	-1924.0%
Net Income	($137M)	($78M)	($209M)	($205M)	($218M)	($152M)	($140M)	($108M)	($71M)	($59M)	($44M)
Net Margin %	-31.7%	-20.6%	-66.7%	-83.5%	-107.0%	-114.9%	-155.3%	-198.0%	-280.2%	-550.9%	-1943.1%
EBITDA	($108M)	($52M)	($177M)	($174M)	($247M)	($144M)	($132M)	($100M)	($64M)	($53M)	($39M)
Earnings Per Share (EPS)	$-2.22	$-1.30	$-3.60	$-3.60	$-4.04	$-3.15	$-3.57	$-3.92	$-2.68	$-3.16	$-2.35
Shares Outstanding (M)	62M	60M	58M	57M	54M	48M	39M	27M	27M	19M	19M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TWST Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$118M	$111M	$104M	$99M	$96M	$93M	$89M	$85M
Gross Profit	$62M	$57M	$54M	$51M	$51M	$46M	$43M	$38M
Gross Margin %	52.8%	51.6%	52.0%	51.3%	53.4%	49.6%	48.3%	45.1%
Operating Income (EBIT)	($36M)	($39M)	($33M)	($30M)	($30M)	($42M)	($35M)	($36M)
Operating Margin %	-30.6%	-34.9%	-31.7%	-30.2%	-31.4%	-44.8%	-39.1%	-42.5%
Net Income	($35M)	($44M)	($31M)	($27M)	$20M	($39M)	($32M)	($35M)
Net Margin %	-29.6%	-39.8%	-29.4%	-27.4%	21.2%	-42.4%	-35.6%	-40.9%
EBITDA	($28M)	($32M)	($27M)	($21M)	$26M	($33M)	($25M)	($28M)
Earnings Per Share (EPS)	$-0.56	$-0.71	$-0.50	$-0.45	$0.33	$-0.66	$-0.53	$-0.60
Shares Outstanding (M)	62M	62M	61M	60M	61M	60M	59M	58M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TWST Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Cash from Operations (CFO)	($53M)	($48M)	($64M)	($142M)	($124M)	($112M)	($142M)	($88M)	($66M)	($51M)	($39M)
Capital Expenditures (CapEx)	$40M	$28M	$5M	$28M	$102M	$27M	$10M	$15M	$4M	$7M	$6M
Free Cash Flow (FCF)	($93M)	($76M)	($69M)	($170M)	($226M)	($139M)	($152M)	($103M)	($70M)	($58M)	($45M)
FCF Margin %	-21.6%	-20.1%	-22.1%	-69.5%	-111.1%	-105.3%	-168.8%	-188.8%	-274.7%	-537.7%	-1975.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TWST Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$1M	($18M)	($25M)	($12M)	($1M)	($13M)	($21M)	($15M)
Capital Expenditures (CapEx)	$10M	$8M	$10M	$12M	$9M	$4M	$2M	$2M
Free Cash Flow (FCF)	($9M)	($26M)	($35M)	($24M)	($11M)	($17M)	($24M)	($17M)
FCF Margin %	-7.2%	-23.1%	-33.6%	-24.5%	-11.0%	-18.5%	-26.7%	-20.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TWST Balance Sheet History

Balance sheet	2026-06-30	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Total Assets	$672M	$642M	$614M	$776M	$961M	$702M	$399M	$187M	$116M	$86M	$76M
Cash & Cash Equivalents	$117M	$183M	$226M	$286M	$379M	$466M	$94M	$47M	$81M	$31M	$29M
Total Liabilities	$227M	$169M	$142M	$153M	$172M	$121M	$63M	$35M	$317M	$219M	$153M
Total Debt (Short + Long-Term)	$9M	$14M	$15M	$15M	$14M	$10M	$11M	$8M	$10M	$18M	$11M
Total Shareholders' Equity	$446M	$473M	$473M	$623M	$789M	$581M	$336M	$152M	($201M)	($133M)	($77M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TWST viewer.

Other Companies in DIAGNOSTICS & RESEARCH

ILMN · Illumina Inc — $36 billion
GH · Guardant Health Inc — $24 billion
MEDP · Medpace Holdings Inc — $17 billion
ICLR · ICON PLC — $13 billion
QGEN · Qiagen NV — $9 billion
RDNT · RadNet Inc — $6 billion
SHC · Sotera Health Co — $5 billion
BLLN · BillionToOne, Inc. Class A Common Stock — $5 billion

← TWSC All “T” companies TWZ →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.